Welcome to the UPF Digital Repository

Browsing Dades primàries de recerca by Author "Rovira Guerín, Ana"

Browsing Dades primàries de recerca by Author "Rovira Guerín, Ana"

Sort by: Order: Results:

  • Tamborero Noguera, David; Rubio Pérez, Carlota; Déu Pons, Jordi; Schroeder, Michael Philipp, 1986-; Vivancos Prellezo, Ana; Rovira Guerín, Ana; Tusquets, Ignasi; Albanell Mestres, Joan; Rodon, Jordi; Tabernero Cartula, Josep; Dienstmann, Rodrigo; González-Pérez, Abel; López Bigas, Núria (Universitat Pompeu Fabra, 2016-10-17)
    The cancer bioMarkers database is curated and maintained by several clinical and scientific experts in the field of precision oncology supported by the European Union’s Horizon 2020 funding. This database is currently being ...
  • Tamborero Noguera, David; Rubio Pérez, Carlota; Déu Pons, Jordi; Schroeder, Michael Philipp, 1986-; Vivancos Prellezo, Ana; Rovira Guerín, Ana; Tusquets, Ignasi; Albanell Mestres, Joan; Tabernero Cartula, Josep; Dienstman, Rodrigo; González-Pérez, Abel; López Bigas, Núria (Universitat Pompeu Fabra, 2016-10)
    This database contains the results of the driver analysis performed by the Cancer Genome Interpreter across 6,792 exomes of a pan-cancer cohort of 28 tumor types. Validated oncogenic mutations are identified according to ...
  • Tamborero Noguera, David; Rubio Pérez, Carlota; Déu Pons, Jordi; Schroeder, Michael Philipp, 1986-; Vivancos Prellezo, Ana; Rovira Guerín, Ana; Tusquets, Ignasi; Albanell Mestres, Joan; Rodon, Jordi; Tabernero Cartula, Josep; Dienstman, Rodrigo; González-Pérez, Abel; López Bigas, Núria (Universitat Pompeu Fabra, 2016-01)
    Bioinformatics method to identify individual driver mutations.
  • Tamborero Noguera, David; Rubio Pérez, Carlota; Déu Pons, Jordi; Schroeder, Michael Philipp, 1986-; Vivancos Prellezo, Ana; Rovira Guerín, Ana; Tusquets, Ignasi; Albanell Mestres, Joan; Rodon, Jordi; Tabernero Cartula, Josep; Dienstman, Rodrigo; González-Pérez, Abel; López Bigas, Núria (Universitat Pompeu Fabra, 2016-10)
    CGI drug prescription assigns targeted drugs to a tumor, based on its genomic alterations, according different levels of evidence (from pre-clinical assays to clinical guidelines).

Search DSpace


Advanced Search

Browse

My Account

Compliant to Partaking